» Articles » PMID: 33598470

Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study

Abstract

Eradication of hepatitis C virus (HCV) promotes an improvement in liver disease and the deactivation of the immune system. Here, we aimed to evaluate the changes in liver disease scores and plasma biomarkers following HCV clearance with direct-acting antivirals (DAAs) in HIV-infected patients with advanced HCV-related cirrhosis. We performed an observational study of 50 patients with advanced cirrhosis who received DAAs therapy. Variables were assessed at baseline and 48 weeks after HCV treatment completion. Epidemiological and clinical data were collected through an online form. Liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), and Child-Pugh-Turcotte (CTP) were evaluated by physicians. Plasma biomarkers were measured by multiplex immunoassay. We found significant decreases in severity scores of liver disease [LSM (-value < 0.001), HVPG (-value = 0.011), and CTP (-value = 0.045)] and plasma biomarkers [LBP (-value < 0.001), IP-10 (-value < 0.001), IL-8 (-value < 0.001), IL-18 (-value < 0.001), IL-1RA (-value = 0.013), OPG (-value < 0.001), sVCAM-1 (-value < 0.001), sICAM-1 (-value < 0.001), PAI-1 (-value = 0.001), and VEGF-A (-value = 0.006)]. We also found a significant direct association between the change in LSM values and the change in values of LBP (-value < 0.001), IP-10 (-value < 0.001), MCP-1 (-value = 0.008), IL-8 (-value < 0.001), IL-18 (-value < 0.001), OPG (-value = 0.004), sVCAM-1 (-value < 0.001), sICAM-1 (-value < 0.001), and PAI-1 (-value = 0.002). For CTP values, we found significant positive associations with IP-10 (-value = 0.010), IL-6 (-value = 0.010), IL-1RA (-value = 0.033), and sICAM-1 (-value = 0.010). The HCV eradication with all-oral DAAs in HIV/HCV-coinfected patients with advanced cirrhosis promoted an improvement in the severity of advanced cirrhosis and plasma biomarkers (inflammation, coagulopathy, and angiogenesis). The decrease in plasma biomarkers was mainly related to the reduction in LSM values.

Citing Articles

PBMCs gene expression predicts liver fibrosis regression after successful HCV therapy in HIV/HCV-coinfected patients.

Virseda-Berdices A, Brochado-Kith O, Berenguer J, Gonzalez-Garcia J, Perez-Latorre L, Busca C Front Pharmacol. 2025; 15:1436198.

PMID: 39911830 PMC: 11794839. DOI: 10.3389/fphar.2024.1436198.


Liver Stiffness Evaluation in Chronic Hepatitis C Patients with Cirrhosis before and after Direct-Acting Antivirals.

Stasi C, Brillanti S Microorganisms. 2024; 12(7).

PMID: 39065186 PMC: 11279336. DOI: 10.3390/microorganisms12071418.


Hepatitis C Virus and the Host: A Mutual Endurance Leaving Indelible Scars in the Host's Immunity.

Mondelli M, Ottolini S, Oliviero B, Mantovani S, Cerino A, Mele D Int J Mol Sci. 2024; 25(1).

PMID: 38203436 PMC: 10779088. DOI: 10.3390/ijms25010268.


DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people.

Gobran S, Pagliuzza A, Khedr O, Fert A, Chomont N, Bruneau J J Virol. 2023; 97(12):e0110523.

PMID: 38051044 PMC: 10734513. DOI: 10.1128/jvi.01105-23.


Reinfection of Transplanted Livers in HCV- and HCV/HIV-Infected Patients Is Characterized by a Different MicroRNA Expression Profile.

Dalla E, Bulfoni M, Cesselli D, Pravisani R, Hidaka M, Eguchi S Cells. 2022; 11(4).

PMID: 35203343 PMC: 8869900. DOI: 10.3390/cells11040690.


References
1.
Lee Y, Hu T, Hung C, Lu S, Chen C, Wang J . The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals. PLoS One. 2019; 14(4):e0214323. PMC: 6445421. DOI: 10.1371/journal.pone.0214323. View

2.
Naggie S . Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time. Top Antivir Med. 2017; 25(1):3-6. PMC: 5677037. View

3.
Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, Turola E . Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. Hepatology. 2018; 68(3):1010-1024. PMC: 6175123. DOI: 10.1002/hep.29911. View

4.
Gonzalez-Reimers E, Quintero-Platt G, Martin-Gonzalez C, Perez-Hernandez O, Romero-Acevedo L, Santolaria-Fernandez F . Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol. 2016; 22(18):4427-37. PMC: 4858626. DOI: 10.3748/wjg.v22.i18.4427. View

5.
Lens S, Alvarado-Tapias E, Marino Z, Londono M, Llop E, Martinez J . Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology. 2017; 153(5):1273-1283.e1. DOI: 10.1053/j.gastro.2017.07.016. View